Global Viral Vector Manufacturing Market Size, Share, Growth, Trends, Company Analysis and Forecast 2020 to 2027

The global viral vector manufacturing market accounted for US$ 228 million in 2019 and is expected to reach US$ 2.4 billion by 2027 growing at a CAGR of 23% during the forecast period 2020 to 2027. The increasing prevalence of target diseases and disorders, a rising number of clinical studies and availability of funding for gene therapy development, and potential applications in novel drug delivery approaches are some of the factors propelling the market growth. However, the excessive cost of gene therapies and possible mutagenesis impede the market.

Viral Vector Manufacturing comprises the generation of these vectors, which then have to be purified in order to meet the quality attributes required for further use as gene delivery systems. Viral or non-viral vector methods are used the inefficient transfer of the therapeutic gene into the target cells. Viral vectors used in gene therapy include adenovirus, lentivirus, retrovirus, and adeno-associated viral (AAV). Non-viral vectors generally depend on delivery of plasmid DNA.

Vectors are living organisms that transmit infectious diseases between humans and from animals to humans. There are several types of viral vectors that are used to deliver nucleic acids into the genetic makeup of cells, including retrovirus, lentivirus, adenovirus, adeno-associated virus, and herpes simplex virus. Viral vectors are highly valued to transfer genetic material into target cells and therefore are explored as vehicles in various therapeutic areas.

Key factors expected to drive growth of the global viral vector manufacturing market is increasing funding in the biopharmaceutical production. In addition, increasing healthcare expenditure, growing ageing population, technological advancement in genetic engineering sector, growing interest in new space of research i.e. gene therapy applications are some other factors expected to drive growth of the global viral vector manufacturing market. Furthermore, increasing accessibility for healthcare facilities, growing demand for effective disease treatments, growing incidence of chronic diseases are some other factors expected to drive growth of the global target market over the forecasted period. However, high cost of manufacturing and gene therapies are factors expected to hamper growth of the global viral vector manufacturing market to a certain extent in the forecast period.

Major players in the viral vector manufacturing process are focusing on enhancing its product portfolio by developing advance technologies and focusing on conducting various clinical trial and R&D activities. In addition, established manufacturers are collaborating with other local players in order to expand geographical presences as well as cater the growing demand for effective treatment mode of diseases. These are some of the trends witnessed in the target market, currently.

Some of the key players profiled in the Viral Vector Manufacturing Market include Spark Therapeutics, Uniqure, Kaneka Eurogentec, Regenxbio, Finvector Vision Therapies, Novasep, Massbiologics, Merck KGaA, Cobra Biologics, Fujifilm Holdings Corporation, Lonza, Brammer Bio, Oxford Biomedica and Thermo Fisher Scientific Inc.

Overview

• Viral vector and plasmid DNA are tools to transfer genetic material into cells. Viral vectors are generally utilized as vectors for gene therapy.
• There are various types of vectors, such as lentivirus, adenovirus, adeno-associated virus (AAV), and others, which include herpes simplex virus and chimeric viral vectors. Plasmid DNA is also employed as a vector in gene therapy and vaccinology. Plasmid DNA is used as raw material in the production of various viral vectors.
• Technological advancements, increase in awareness about viral vector-based treatments, and rise in demand for vector-based products for research are the major factors anticipated to drive the global viral vector & plasmid DNA manufacturing market during the forecast period
• North America held major share of the global viral vector & plasmid DNA manufacturing market in 2018. Availability of the U.S. FDA (Food and Drug Administration) approved gene therapy products and rich product pipeline are the factors expected to augment the viral vector & plasmid DNA manufacturing market in the region during the forecast period.
• The viral vector & plasmid DNA manufacturing market in Asia Pacific is likely to expand at a high CAGR of 24.5% from 2019 to 2027, due to recent developments in regenerative medicines, rise in prevalence of chronic diseases, and increase in demand for gene therapies. Additionally, demand for viral vector & plasmid DNA is increasing in emerging markets such as India and China.

Rise in Prevalence of Cancer, Genetic Diseases, and Infectious Diseases to Propel Global Viral Vector & Plasmid DNA Manufacturing Market

• Rise in prevalence of cancer and genetic diseases is projected to augment the global viral vector & plasmid DNA manufacturing market during the forecast period
• According to the Cancer Research UK, 17 million new cases of cancer were reported globally in 2018 and the four most common types of cancer were breast, lung, bowel, and prostate, which account for around 43% of all new cases
• According to the National Cancer Institute, cancer is among the leading causes of death across the world, and the number of new cases per year is anticipated to rise to 23.6 million by 2030.

Plasmid DNA Segment Dominated Global Viral Vector & Plasmid DNA Manufacturing Market

• In terms of type, the global viral vector & plasmid DNA manufacturing market can be classified into lentivirus, adenovirus, adeno-associated virus (AAV), plasmid DNA, and others
• The plasmid DNA segment dominated the global viral vector & plasmid DNA manufacturing market in 2018 and the trend is expected to continue during the forecast period
• Increase in use of plasmid DNA as raw material in the manufacture of viral vectors is likely to drive the segment during the forecast period

Cancer to be Promising Segment of Global Viral Vector & Plasmid DNA Manufacturing Market

• Based on disease, the global viral vector & plasmid DNA manufacturing market has been categorized into genetic disorders, cancer, infectious diseases, and others
• The cancer segment dominated the global viral vector & plasmid DNA manufacturing market in 2018 and the trend is projected to continue during the forecast period owing to large number of ongoing clinical trials and availability of approved viral vector-based cancer drugs

Biotech Companies to be Lucrative Segment of Global Viral Vector & Plasmid DNA Manufacturing Market

• In terms of end-user, the global viral vector & plasmid DNA manufacturing market has been categorized into biotech companies and research institutes
• The biotech companies segment held major share of the global viral vector & plasmid DNA manufacturing market in 2018
• Increase in number of viral vector-based cancer drugs being manufactured by multinational players and several clinical trials underway for the treatment of various cancers are anticipated to propel the segment during the forecast period

North America to Dominate Global Market; Asia Pacific to Offer Significant Incremental Opportunity

• In terms of region, the global viral vector & plasmid DNA manufacturing market has been segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa
• North America is projected to account for major share of the global viral vector & plasmid DNA manufacturing market during the forecast period, owing to high acceptance of viral vector-based gene therapies for the treatment of rare diseases and availability of FDA-approved gene therapies
• The viral vector & plasmid DNA manufacturing market in Asia Pacific is anticipated to grow at a rapid pace in the next few years. Several ongoing gene therapy clinical trials in countries in China and Japan and high incidence of cancer are likely to fuel the growth of the market in the emerging countries of Asia Pacific

Segmentation:

Segmentation by type:

• Retrovirus
• Gammaretrovirus
• Adeno-associated virus (AAV)
• Other Viral Vectors (includes Lentiviral Vectors, Herpes Simplex Virus Vectors, etc.)

Segmentation by diseases:

• Cancer
• Infectious Disease
• Genetic Disorders

Segmentation by application:

• Gene Therapy
• Vaccinology

Segmentation by end user:

• Biotech companies
• Research Institutes

Segmentation by region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

What our report offers:

• Market share assessments for the regional and country level segments
• Strategic recommendations for the new entrants
• Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic analysis: Drivers and Constraints, Product/Technology Analysis, Porter's five forces analysis, SWOT analysis etc.
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements